Cargando…
Preoperative Chemoradiotherapy with Capecitabine and Oxaliplatin in Locally Advanced Rectal Cancer. A Phase I–II Multicenter Study of the Dutch Colorectal Cancer Group
BACKGROUND: We studied the maximum tolerated dose (MTD) and efficacy of oxaliplatin added to capecitabine and radiotherapy (Capox-RT) as neoadjuvant therapy for rectal cancer. METHODS: T3-4 rectal cancer patients received escalating doses of oxaliplatin (day 1 and 29) with a fixed dose of capecitabi...
Autores principales: | Hospers, Geke A., Punt, Cornelis J. A., Tesselaar, Margot E., Cats, Annemieke, Havenga, Klaas, Leer, Jan W. H., Marijnen, Corrie A., Jansen, Edwin P., Van Krieken, Han H. J. M., Wiggers, Theo, Van de Velde, Cornelis J. H., Mulder, Nanno H. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2007
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2039827/ https://www.ncbi.nlm.nih.gov/pubmed/17653805 http://dx.doi.org/10.1245/s10434-007-9396-6 |
Ejemplares similares
-
Short-Course Radiotherapy Followed by Neoadjuvant Bevacizumab, Capecitabine, and Oxaliplatin and Subsequent Radical Treatment in Primary Stage IV Rectal Cancer: Long-Term Results of a Phase II Study
por: Bisschop, C., et al.
Publicado: (2017) -
Highlights from the seventh European Multidisciplinary Colorectal Cancer Congress (EMCCC) 2014
por: Punt, Cornelis JA, et al.
Publicado: (2015) -
Current controversies in TNM for the radiological staging of rectal cancer and how to deal with them: results of a global online survey and multidisciplinary expert consensus
por: Lambregts, Doenja M. J., et al.
Publicado: (2022) -
Cytoreduction and HIPEC in The Netherlands: Nationwide Long-term Outcome Following the Dutch Protocol
por: Kuijpers, Anke M. J., et al.
Publicado: (2013) -
Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review
por: Wang, H. H., et al.
Publicado: (2023)